Cargando…

Systemic lupus erythematosus and thrombosis

Systemic Lupus Erythematosus (SLE) is an acquired, multiorgan, autoimmune disease. Clinical presentation is extremely variable and heterogeneous. It has been shown that SLE itself is an independent risk factor for developing both arterial and venous thrombotic events since SLE patients have an Odds...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazzan, Mario, Vaccarino, Antonella, Marletto, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407320/
https://www.ncbi.nlm.nih.gov/pubmed/25908929
http://dx.doi.org/10.1186/s12959-015-0043-3
_version_ 1782367888369254400
author Bazzan, Mario
Vaccarino, Antonella
Marletto, Fabio
author_facet Bazzan, Mario
Vaccarino, Antonella
Marletto, Fabio
author_sort Bazzan, Mario
collection PubMed
description Systemic Lupus Erythematosus (SLE) is an acquired, multiorgan, autoimmune disease. Clinical presentation is extremely variable and heterogeneous. It has been shown that SLE itself is an independent risk factor for developing both arterial and venous thrombotic events since SLE patients have an Odds Ratio (OR) for thrombosis that varies depending on the clinical and laboratory characteristics of each study cohort. The risk of developing a thrombotic event is higher in this setting than in the general population and may further increase when associated with other risk factors, or in the presence of inherited or acquired pro-thrombotic abnormalities, or trigger events. In particular, a striking increase in the number of thrombotic events was observed when SLE was associated with antiphospholipid antibodies (aPL). The presence of aPLs has been described in about 50% of SLE patients, while about 20% of antiphospholipid syndrome (APS) patients have SLE. While APS patients (with or without an autoimmune disease) have been widely studied in the last years, fewer studies are available for SLE patients and thrombosis in the absence of APS. Although the available literature undoubtedly shows that SLE patients have a greater prevalence of thrombotic events as compared to healthy subjects, it is difficult to obtain a definite result from these studies because in some cases the study cohort was too small, in others it is due to the varied characteristics of the study population, or because of the different (and very copious) laboratory assays and methods that were used. When an SLE patient develops a thrombotic event, it is of great clinical relevance since it is potentially life-threatening. Moreover, it worsens the quality of life and is a clinical challenge for the clinician.
format Online
Article
Text
id pubmed-4407320
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44073202015-04-24 Systemic lupus erythematosus and thrombosis Bazzan, Mario Vaccarino, Antonella Marletto, Fabio Thromb J Review Systemic Lupus Erythematosus (SLE) is an acquired, multiorgan, autoimmune disease. Clinical presentation is extremely variable and heterogeneous. It has been shown that SLE itself is an independent risk factor for developing both arterial and venous thrombotic events since SLE patients have an Odds Ratio (OR) for thrombosis that varies depending on the clinical and laboratory characteristics of each study cohort. The risk of developing a thrombotic event is higher in this setting than in the general population and may further increase when associated with other risk factors, or in the presence of inherited or acquired pro-thrombotic abnormalities, or trigger events. In particular, a striking increase in the number of thrombotic events was observed when SLE was associated with antiphospholipid antibodies (aPL). The presence of aPLs has been described in about 50% of SLE patients, while about 20% of antiphospholipid syndrome (APS) patients have SLE. While APS patients (with or without an autoimmune disease) have been widely studied in the last years, fewer studies are available for SLE patients and thrombosis in the absence of APS. Although the available literature undoubtedly shows that SLE patients have a greater prevalence of thrombotic events as compared to healthy subjects, it is difficult to obtain a definite result from these studies because in some cases the study cohort was too small, in others it is due to the varied characteristics of the study population, or because of the different (and very copious) laboratory assays and methods that were used. When an SLE patient develops a thrombotic event, it is of great clinical relevance since it is potentially life-threatening. Moreover, it worsens the quality of life and is a clinical challenge for the clinician. BioMed Central 2015-04-23 /pmc/articles/PMC4407320/ /pubmed/25908929 http://dx.doi.org/10.1186/s12959-015-0043-3 Text en © Bazzan et al. ; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Bazzan, Mario
Vaccarino, Antonella
Marletto, Fabio
Systemic lupus erythematosus and thrombosis
title Systemic lupus erythematosus and thrombosis
title_full Systemic lupus erythematosus and thrombosis
title_fullStr Systemic lupus erythematosus and thrombosis
title_full_unstemmed Systemic lupus erythematosus and thrombosis
title_short Systemic lupus erythematosus and thrombosis
title_sort systemic lupus erythematosus and thrombosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407320/
https://www.ncbi.nlm.nih.gov/pubmed/25908929
http://dx.doi.org/10.1186/s12959-015-0043-3
work_keys_str_mv AT bazzanmario systemiclupuserythematosusandthrombosis
AT vaccarinoantonella systemiclupuserythematosusandthrombosis
AT marlettofabio systemiclupuserythematosusandthrombosis